Previous Section
Clinical Trials
11. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
- Author
- Cortes J; Quintas-Cardama A; Garcia-Manero G; O'Brien S; Jones D; Faderl S; Ebarb T; Giles F; Thomas D; Kantarjian H;
- Institution
- Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. jcortes@mdahderson.org
- Journal
- Cancer. 2007 Nov 1;110(9):2000-6.
- Abstract URL
- Click here to view abstract
12. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
- Author
- Quintas-Cardama A; Kantarjian H; O'brien S; Borthakur G; Bruzzi J; Munden R; Cortes J;
- Institution
- Department of Leukemia and Department of Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. aquintas@mdanderson.org
- Journal
- J Clin Oncol. 2007 Sep 1;25(25):3908-14.
- Abstract URL
- Click here to view abstract
13. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
- Author
- Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H;
- Institution
- Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. jcortes@mdanderson.org
- Journal
- Cancer. 2007 Sep 15;110(6):1295-302.
- Abstract URL
- Click here to view abstract
14. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
- Author
- Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K;
- Institution
- Division of Molecular Pathology, Institute of Medical and Veterinary Science, Adelaide, SA, Australia. susan.branford@imvs.sa.gov.au
- Journal
- Cancer. 2007 Aug 15;110(4):801-8.
- Abstract URL
- Click here to view abstract
15. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
- Author
- Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M;
- Institution
- M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. jcortes@mdanderson.org
- Journal
- Blood. 2007 Apr 15;109(8):3207-13. Epub 2006 Dec 21.
- Abstract URL
- Click here to view abstract
16. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
- Author
- Oki Y; Kantarjian HM; Gharibyan V; Jones D; O'brien S; Verstovsek S; Cortes J; Morris GM; Garcia-Manero G; Issa JP;
- Institution
- Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
- Journal
- Cancer. 2007 Mar 1;109(5):899-906.
- Abstract URL
- Click here to view abstract
17. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party.
- Author
- Rosti G; Iacobucci I; Bassi S; Castagnetti F; Amabile M; Cilloni D; Poerio A; Soverini S; Palandri F; Rege Cambrin G; Iuliano F; Alimena G; Latagliata R; Testoni N; Pane F; Saglio G; Baccarani M; Martinelli G;
- Institution
- Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy.
- Journal
- Haematologica. 2007 Jan;92(1):101-5.
- Abstract URL
- Click here to view abstract
18. Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
- Author
- Ringhoffer M; Harsdorf S; Schmitt M; Wiesneth M; Zenz T; Stilgenbauer S; Greiner J; Dohner K; Marx M; Dohner H; Bunjes D;
- Institution
- Third Department of Medicine, University Hospital of Ulm, Ulm, Germany.
- Journal
- Br J Haematol. 2007 Jan;136(1):127-30.
- Abstract URL
- Click here to view abstract
19. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
- Author
- Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA; Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
- Institution
- Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA. drukerb@ohsu.edu
- Journal
- N Engl J Med. 2006 Dec 7;355(23):2408-17.
- Abstract URL
- Click here to view abstract
20. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
- Author
- Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhauser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T;
- Institution
- III. Med. Klinik, Johannes Gutenberg-University, Mainz; University of Ulm, II. Med. Klinik, Charite, Germany.
- Journal
- J Clin Oncol. 2005 Oct 20;23(30):7583-93.
- Abstract URL
- Click here to view abstract
Next: Immunotherapy
